Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells
- PMID:2675614
- PMCID: PMC1879920
Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells
Abstract
Adult cats determined by clinical laboratory evaluations to be normal, impaired glucose tolerant, or overtly diabetic were used to explore prospectively the relationships among pancreatic beta cell islet amyloid polypeptide (IAPP) immunoreactivity, islet amyloid (IA) deposition, and diabetogenesis. IAPP-derived IA was found in 11 of 14 (79%) diabetic cats, in four of nine (44%) impaired glucose tolerant cats, and in two of eight (25%) normal adult cats. The presence of IA even in very small amounts, therefore, predicts a very high probability (88%) that an animal has either impaired glucose tolerance or overt DM. Although all overtly diabetic cats had a marked decrease or absence of beta cell IAPP immunoreactivity, six of six cats with impaired glucose tolerance retained IAPP immunoreactivity with 1:15,000 dilutions of antisynthetic IAPP 7-17, whereas only one of seven normal cats had IAPP immunoreactivity beyond 1:10,000 dilutions. These findings suggest that increased IAPP production preceding the development of overt DM is linked to the progressive formation of insoluble IA deposits that are apparent in most overtly diabetic individuals. Of most importance, in that IAPP has been reported to inhibit both basal and insulin-stimulated rates of glycogen synthesis, is the possibility that increased production and release of IAPP by pancreatic beta cells plays a key role in the development of the insulin resistance and impaired glucose tolerance, both of which occur in Type 2 DM.
Similar articles
- Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus.Johnson KH, O'Brien TD, Betsholtz C, Westermark P.Johnson KH, et al.N Engl J Med. 1989 Aug 24;321(8):513-8. doi: 10.1056/NEJM198908243210806.N Engl J Med. 1989.PMID:2668761Review.
- Quantitative immunohistochemical analysis of islet amyloid polypeptide (IAPP) in normal, impaired glucose tolerant, and diabetic cats.Ma Z, Westermark GT, Johnson KH, O'Brien TD, Westermark P.Ma Z, et al.Amyloid. 1998 Dec;5(4):255-61. doi: 10.3109/13506129809007298.Amyloid. 1998.PMID:10036583
- Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques.Johnson KH, O'Brien TD, Hayden DW, Jordan K, Ghobrial HK, Mahoney WC, Westermark P.Johnson KH, et al.Am J Pathol. 1988 Jan;130(1):1-8.Am J Pathol. 1988.PMID:3276206Free PMC article.
- Islet amyloid polypeptide (IAPP) and pancreatic islet amyloid deposition in diabetic and non-diabetic patients.Narita R, Toshimori H, Nakazato M, Kuribayashi T, Toshimori T, Kawabata K, Takahashi K, Masukura S.Narita R, et al.Diabetes Res Clin Pract. 1992 Jan;15(1):3-14. doi: 10.1016/0168-8227(92)90060-5.Diabetes Res Clin Pract. 1992.PMID:1541232
- Islet amyloid polypeptide: a review of its biology and potential roles in the pathogenesis of diabetes mellitus.O'Brien TD, Butler PC, Westermark P, Johnson KH.O'Brien TD, et al.Vet Pathol. 1993 Jul;30(4):317-32. doi: 10.1177/030098589303000401.Vet Pathol. 1993.PMID:8212454Review.
Cited by
- Amylin at the interface between metabolic and neurodegenerative disorders.Lutz TA, Meyer U.Lutz TA, et al.Front Neurosci. 2015 Jun 16;9:216. doi: 10.3389/fnins.2015.00216. eCollection 2015.Front Neurosci. 2015.PMID:26136651Free PMC article.Review.
- The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease.Grizzanti J, Lee HG, Camins A, Pallas M, Casadesus G.Grizzanti J, et al.Nutr Res. 2016 Dec;36(12):1305-1315. doi: 10.1016/j.nutres.2016.11.002. Epub 2016 Nov 8.Nutr Res. 2016.PMID:27923524Free PMC article.Review.
- Islet amyloid polypeptide: demonstration of mRNA in human pancreatic islets by in situ hybridization in islets with and without amyloid deposits.Westermark GT, Christmanson L, Terenghi G, Permerth J, Betsholtz C, Larsson J, Polak JM, Westermark P.Westermark GT, et al.Diabetologia. 1993 Apr;36(4):323-8. doi: 10.1007/BF00400235.Diabetologia. 1993.PMID:8477877
- Role of islet amyloid polypeptide secretion in insulin-resistant humans.Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhäusl W, Prager R.Kautzky-Willer A, et al.Diabetologia. 1994 Feb;37(2):188-94. doi: 10.1007/s001250050092.Diabetologia. 1994.PMID:8163054
- A feline model of experimentally induced islet amyloidosis.Hoenig M, Hall G, Ferguson D, Jordan K, Henson M, Johnson K, O'Brien T.Hoenig M, et al.Am J Pathol. 2000 Dec;157(6):2143-50. doi: 10.1016/S0002-9440(10)64852-3.Am J Pathol. 2000.PMID:11106586Free PMC article.
References
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous